Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended-treatment or follow-up ipilimumab monotherapy in advanced melanoma
2005-006083-57Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ipilimumab in melanoma (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Safety of ipilimumab. Started Jul 2006; status: completed.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2005-006083-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-006083-57.